CG Jul 2023 45.000 call
| Previous close | 0.5100 |
| Open | 0.5100 |
| Bid | 0.7500 |
| Ask | 1.2500 |
| Strike | 45.00 |
| Expiry date | 2023-07-21 |
| Day's range | 0.5100 - 0.5100 |
| Contract range | N/A |
| Volume | |
| Open interest | 42 |
- Bloomberg
Diamond Raids Deliver Carlyle-Backed Fund €50 Million Gem Haul
(Bloomberg) -- Raids across more than a dozen properties around the Belgian diamond enclave of Antwerp seized roughly €50 million ($55 million) of the precious stones in an attempt to recover debts tied to the collapse of one of the country’s largest traders.Most Read from BloombergMerck Covid Drug Linked to New Virus Mutations, Study SaysAdani Crisis Deepens as Stock Rout Hits $108 BillionPorsche Blunder Puts $148,000 Sportscar on Sale for Just $18,000Plenty of Americans Are Drinking Bleach, St
- PR Newswire
AlphaStruxure to Design, Construct, and Operate JFK's New Terminal One Microgrid, Creating the Largest Rooftop Terminal Solar Array in the U.S.
Today, AlphaStruxure, a leader in Energy as a Service (EaaS) solutions, announced an agreement to design, construct, and operate integrated microgrid infrastructure at the New Terminal One (NTO) at John F. Kennedy International Airport. The microgrid will provide NTO with sustainable, resilient, locally generated, and cost-predictable energy. It will deliver immediate greenhouse gas emission reductions of 38 percent over grid-sourced energy and lead to cleaner air for the surrounding communities
- PR Newswire
Pathalys Pharma Raises $150 Million in Secured Product Financing and Equity led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics to Advance Upacicalcet through Pivotal Phase 3 Studies
Pathalys Pharma, Inc., a private, late-stage biopharma company co-founded by Catalys Pacific and DaVita Venture Group, and Launch Therapeutics (Launch Tx), a clinical development company, today announced a collaboration to advance phase 3 clinical trials for upacicalcet (designated PLS240 for clinical trials) for the treatment of secondary hyperparathyroidism (SHPT) in patients on hemodialysis. Launch Tx is backed by funds managed by global investment firm Carlyle (NASDAQ: CG) and its life scien
